Hyeseon Cho,Kristina Kay Gonzales-Wartz,Deli Huang,Meng Yuan,Mary Peterson,Janie Liang,Nathan Beutler,Jonathan L. Torres,Yu Cong,Elena Postnikova,Sandhya Bangaru,Chloe Adrienna Talana,Wei Shi,Eun Sung Yang,Yi Zhang,Kwanyee Leung,Lingshu Wang,Linghang Peng,Jeff Skinner,Shanping Li,Nicholas C. Wu,Hejun Liu,Cherrelle Dacon,Thomas Moyer,Melanie Cohen,Ming Zhao,Frances Eun-Hyung Lee,Rona S. Weinberg,Iyadh Douagi,Robin Gross,Connie Schmaljohn,Amarendra Pegu,John R. Mascola,Michael Holbrook,David Nemazee,Thomas F. Rogers,Andrew B. Ward,Ian A. Wilson,Peter D. Crompton,Joshua Tan

Abstract:The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern threatens the efficacy of existing vaccines and therapeutic antibodies and underscores the need for additional antibody-based tools that potently neutralize variants by targeting multiple sites of the spike protein. We isolated 216 monoclonal antibodies targeting SARS-CoV-2 from plasmablasts and memory B cells collected from patients with coronavirus disease 2019. The three most potent antibodies targeted distinct regions of the receptor binding domain (RBD), and all three neutralized the SARS-CoV-2 Alpha and Beta variants. The crystal structure of the most potent antibody, CV503, revealed that it binds to the ridge region of SARS-CoV-2 RBD, competes with the angiotensin-converting enzyme 2 receptor, and has limited contact with key variant residues K417, E484, and N501. We designed bispecific antibodies by combining nonoverlapping specificities and identified five bispecific antibodies that inhibit SARS-CoV-2 infection at concentrations of less than 1 ng/ml. Through a distinct mode of action, three bispecific antibodies cross-linked adjacent spike proteins using dual N-terminal domain–RBD specificities. One bispecific antibody was greater than 100-fold more potent than a cocktail of its parent monoclonals in vitro and prevented clinical disease in a hamster model at a dose of 2.5 mg/kg. Two bispecific antibodies in our panel comparably neutralized the Alpha, Beta, Gamma, and Delta variants and wild-type virus. Furthermore, a bispecific antibody that neutralized the Beta variant protected hamsters against SARS-CoV-2 expressing the E484K mutation. Thus, bispecific antibodies represent a promising next-generation countermeasure against SARS-CoV-2 variants of concern.

Emerging anti-spike monoclonal antibodies against SARS-CoV-2

Bispecific Antibodies Targeting Distinct Regions of the Spike Protein Potently Neutralize SARS-CoV-2 Variants of Concern

Ultrapotent Bispecific Antibodies Neutralize Emerging SARS-CoV-2 Variants

An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies

Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

Neutralization of SARS-CoV-2 Omicron BA.2 by Therapeutic Monoclonal Antibodies.

Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19

Broadly potent spike-specific human monoclonal antibodies inhibit SARS-CoV-2 Omicron sub-lineages

A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes

Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants

Neutralizing monoclonal antibodies for treatment of COVID-19

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

A Broadly Neutralizing Antibody Inhibits SARS-CoV-2 Variants Through a Novel Mechanism of Disrupting Spike Trimer Integrity

Characterization of monoclonal antibodies targeting SARS-CoV-2 spike glycoprotein: Reactivity against Delta and Omicron BA. 1 variants

Monoclonal Antibodies Capable of Binding SARS-CoV-2 Spike Protein Receptor-Binding Motif Specifically Prevent GM-CSF Induction.

A SARS-CoV-2 neutralizing antibody with exceptional spike binding coverage and optimized therapeutic potentials

Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants

Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike